William Carter

$GNS we’re very likely halted until 11/20. Confirmed 7 other examples with our same price situation: Bullish

$IBRX there has already been il-15 studies done with mice and sepsis. Great results. Improves survival. Posted links to the studies in comments on Dr. Patrick's post. Here are quotes from one of them. "In conclusion, IL-15 prevents two immunopathologic hallmarks of sepsis, namely, apoptosis and immunosuppression, and improves survival in two different models of sepsis. IL-15 represents a potentially novel therapy of this highly lethal disorder." "A second trial of IL-15 was undertaken in which IL-15 was administered 6 h after CLP and mice treated with IL-15 had a 3-fold improvement in survival compared with CLP mice that did not receive IL-15 (Fig. 8). IL-15 induced a similar improvement in survival in the P. aeruginosa pneumonia model. Mice treated with IL-15 had a 2-fold improvement in survival compared with control mice." We know the power of il-15. An il-15 superagonist takes it to the next level.

$BB BMO Technology and Innovation Leaders Conference – November 12, 2026, New York, NY Grant Courville, Senior Vice President of Products and Strategy for QNX, will hold one-on-one meetings with institutional investors. There will be no formal presentations or webcasts for this event. RBC Capital Markets Global TIMT Conference – November 17, 2026, New York, NY Chief Financial Officer Tim Foote and QNX President John Wall will participate in a "fireside chat" (beginning at 2:40 PM ET) and hold meetings with institutional investors. 18th Annual TD Cowen Canada Technology Conference – November 24, 2026, Toronto, ON Chief Financial Officer Tim Foote and QNX President John Wall will participate in a "fireside chat" (beginning at 3:00 PM ET) and hold meetings with institutional investors. The "fireside chat" sessions at the RBC Capital Markets conference and the TD Cowen conference will be webcast via the BlackBerry Investor Relations website.

$TE okay now I know we are selling off …I think we are done here Tesla has officially started construction of its massive new $10 billion solar manufacturing facility near Houston, Texas! Construction is expected to finish in 2028, with commercial operations starting in Q1 2029. Total direct and indirect economic impact of the project is estimated to generate ~$6.4B in state and local taxes, and increase State of Texas GDP by ~$107 billion. The factory will be a vertically integrated solar manufacturing facility, and it'll include: • Wafer Manufacturing • Ingot Manufacturing • Coating • Metallization and Printing Lines • Cell Testing and QC • Automation and Material Handling • Cleanroom and Production Support • Site Infrastructure • Chemical Storage and Delivery • Utility Infrastructure • Environmental and Safety Systems

$DVLT ✅🗞️🫵🏼DVLT (Datavault AI) is showing positive momentum on November 11, but I see a few possible reasons behind the buying interest. What's driving the optimism? New business collaboration: Datavault announced a global partnership with Biochar Now involving carbon-removal credits and its tokenization technology.  New CEO: Brett Moyer was appointed CEO following the removal of Nathaniel Bradley. Investors may be hoping the leadership change improves confidence.  AI-sector momentum: Technology stocks are benefiting from renewed enthusiasm around AI infrastructure.

$GME Ryan, please take notes. this is what companies do to their loyal shareholders...

$SLS The market is blinded by Moderna’s personalized mRNA hype, failing to look under the hood. Let's compare their Phase 3 metrics against the hard-coded reality of the SELLAS platform: Moderna’s Phase 3 INTerpath-001 hit a headline Recurrence-Free Survival (RFS) Hazard Ratio (HR) of 0.58. The catch? They did NOT deliver on the gold standard endpoint—Overall Survival (OS) remains immature. They track months to a scan recurrence, not uncompromised extension of human life. SELLAS doesn’t hide behind soft proxies. Phase 3 REGAL is hard-coded around the ultimate regulatory bar: Overall Survival (OS) in hyper-aggressive AML CR2. THE GOLD STANDARD. While MRNA tracks a scan, 46 REGAL survivors are still living past 30 months in a disease that historically kills in 6-8 months. Ad Infinitum. Fuck cancer.

$NWBO Hey you negative Nancy’s out there. Get a load of this- Saturday, Nov 14: Society of Neurological Oncology (SNO) conference Dr. Prins presents again the results of the ATL-DC/PD-1 mAb Blockade trial which showed Median overall survival for IDH wild type patients was 555 days (18.2 months) (95% CI, 347–810) in Arm B patients (n=16) who received ATL-DC/poly ICLC followed by PD-1 mAb blockade. No other trial has ever shown more than a 9 month OS benefit in rGBM. ATL-DC/PD-1 is what they’re calling DCVax-L in this study. Can you say double the benefit without cursing that something worked to help people with a deadly aggressive disease.

$ONDS ...........NOW is the TIME $$$...SHOW Us the Money $$

$NIO block out the noise and know what you're invested in. NIO's Shenji chip unit establishes a new wholly-owned subsidiary in Shenzhen to expand commercial sales Official and news reporting published on November 10, 2026 confirm that NIO's semiconductor arm, GeniTech (also known as Shenji), has established a new wholly-owned subsidiary in Shenzhen. The new entity will focus on chip sales, software development, and smart hardware sales, marking another step in commercializing the chip business beyond NIO's internal vehicle ecosystem.

$IREN Shorts are cooked in this Neocloud sector at these prices 🚀

$CBRS November 12 Thursday | After U.S. Market Close Q3 2026 Financial Results and Conference Call Key Focus Areas: Whether revenue growth exceeds expectations. Order growth for AI inference-related business. Gross margin and operating losses. Guidance for orders and revenue for 2027. Reliability of wafer-level chips and progress on customer deployments.

$OPEN I know Opendoor’s “Own” product is only in testing in one state, but given the current market, I still think Kaz should’ve talked about it on the call. Could’ve helped ease the blow. They do it through Ownify. Here’s the details how it works. The beginning of Opendoor’s tokenization effort it seems:

$GRRR chi cuole si sfoghi...